ITM11 Expanded Access Program for Patients
Sponsor: ITM Solucin GmbH
ClinicalTrials ID:NCT07497984
This program allows patients to access the investigational treatment ITM-11 before it is officially approved by health authorities in their country. Availability depends on the country's eligibility, and the decision to participate is made by the treating doctor based on the patient's medical history and program criteria.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The ITM11 Expanded Access Program is designed to provide patients with access to the treatment ITM-11 before it receives official approval from local health authorities. The program is available in certain countries, and eligibility is determined by the treating physician. The doctor will assess whether the potential benefits of using this investigational treatment outweigh the risks for each patient, based on their medical history and the program's eligibility criteria.
Eligibility Criteria
Inclusion Criteria
-
Exclusion Criteria
-
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.